Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomised, Double-blind, Parallel-group Phase III Study to Assess High Dose Esomeprazole Na i.v. Treatment (Bolus Infusion of 80 mg Followed by a Continuous Infusion of 8 mg Per Hour Administered for 72 Hours) for Prevention of Rebleeding

NCT01757275 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01757275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01757275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomised, Double-blind, Parallel-group Phase III Study to Assess High Dose Esomeprazole Na i.v. Treatment (Bolus Infusion of 80 mg Followed by a Continuous Infusion of 8 mg Per Hour Administered for 72 Hours) for Prevention of Rebleeding
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2013
Completion date
December 31, 2014
Enrollment
239 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

bleeding peptic ulcer